

## S 2254

### Medicare PBM Accountability Act

**Congress:** 118 (2023–2025, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Jul 12, 2023

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Jul 12, 2023)

**Official Text:** <https://www.congress.gov/bill/118th-congress/senate-bill/2254>

## Sponsor

**Name:** Sen. Cortez Masto, Catherine [D-NV]

**Party:** Democratic • **State:** NV • **Chamber:** Senate

## Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Crapo, Mike [R-ID]	R · ID		Jul 12, 2023
Sen. Tillis, Thomas [R-NC]	R · NC		Jul 12, 2023
Sen. Wyden, Ron [D-OR]	D · OR		Jul 12, 2023

## Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jul 12, 2023

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
118 HR 5385	Identical bill	Dec 17, 2024: Referred to the Subcommittee on Health.
118 S 2973	Related bill	Dec 7, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 266.

## **Medicare PBM Accountability Act**

This bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.

Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.

In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

## **Actions Timeline**

---

- **Jul 12, 2023:** Introduced in Senate
- **Jul 12, 2023:** Read twice and referred to the Committee on Finance.